Physician profile
Tamara Miller
NPI 1982659017
$1,426,284.40
in general payments reported to CMS, 2019-2025
82 companies · $209K in 2025
The $209K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $241K · 2020: $142K · 2021: $186K · 2022: $236K · 2023: $193K · 2024: $218K · 2025: $209K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $452K · Travel and Lodging: $59K · Consulting Fee: $56K · Food and Beverage: $28K · Honoraria: $24K · Education: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $452,334.00 |
| Travel and Lodging | $58,992.83 |
| Consulting Fee | $56,452.24 |
| Food and Beverage | $28,103.74 |
| Honoraria | $24,430.00 |
| Education | $175.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $259,106.82 | 2020-2025 | |
| Emd Serono, INC. | $206,409.82 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $152,762.97 | 2019-2025 | |
| Genentech USA, INC. | $119,648.87 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Allergan, INC. | $105,532.30 | 2019-2022 | |
| Tg Therapeutics, INC. | $97,826.58 | 2021-2025 | Briumvi |
| Biogen, INC. | $87,075.01 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Amgen INC. | $83,729.11 | 2019-2025 | Aimovig, Uplizna |
| Biohaven Pharmaceutical Holding Company Ltd. | $52,030.42 | 2022 | |
| Lundbeck LLC | $51,601.45 | 2020-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $50,336.90 | 2020-2021 | |
| Pfizer INC. | $28,959.29 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $26,693.07 | 2019-2025 | Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $21,687.86 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| E.R. Squibb & Sons, L.L.C. | $18,300.49 | 2020-2023 |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $17,553.07 | 2019-2025 | Zeposia |
| Impel Pharmaceuticals INC. | $10,768.50 | 2022 | |
| Mallinckrodt Enterprises LLC | $9,450.53 | 2019 | |
| Mdd US Operations, LLC | $8,241.64 | 2019-2024 | Gocovri, Gocovri |
| Mallinckrodt Hospital Products INC. | $3,918.83 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $2,262.12 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $2,157.75 | 2019-2025 | Ultomiris, Soliris |
| Ipsen Innovation | $1,657.61 | 2024 | |
| Ucb, INC. | $1,392.44 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Livanova USA, INC. | $1,160.24 | 2019 | |
| Sk Life Science, INC. | $685.78 | 2020-2025 | Xcopri |
| Horizon Therapeutics Plc | $525.46 | 2021-2023 | Uplizna |
| Acorda Therapeutics, INC | $403.98 | 2019-2023 | Ampyra |
| Supernus Pharmaceuticals, INC. | $375.71 | 2019-2022 | |
| Grt US Holding, INC. | $353.01 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $267.20 | 2019-2023 | Rytary, Lyvispah |
| Neurocrine Biosciences, INC. | $251.50 | 2019-2025 | Ingrezza |
| Csl Behring | $227.77 | 2020-2025 | Hizentra |
| Neurelis, INC. | $197.11 | 2021-2025 | Valtoco |
| Avanir Pharmaceuticals, INC. | $181.43 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $176.45 | 2024-2025 | |
| Banner Life Sciences, LLC | $157.40 | 2021-2024 | |
| Eisai INC. | $146.90 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $135.86 | 2021-2025 | Xeomin, Ampyra, Inbrija |
| Tanabe Pharma America, INC. | $133.28 | 2020-2025 | Radicava |
| Ani Pharmaceuticals, INC. | $120.46 | 2024-2025 | Purified Cortrophin Gel |
| Grifols USA, LLC | $119.72 | 2019-2024 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $116.69 | 2021-2022 | |
| Argenx US, INC. | $106.88 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $103.30 | 2022-2025 | Epidiolex |
| Medtronic, INC. | $100.99 | 2024 | Synchromedii |
| Abbott Laboratories | $97.74 | 2022-2025 | Infinity |
| Acadia Pharmaceuticals INC | $84.86 | 2019-2025 | Nuplazid |
| Bausch Health US, LLC | $81.83 | 2019-2024 | Aplenzin |
| Vanda Pharmaceuticals INC. | $58.84 | 2025 | Ponvory |
| Averitas Pharma INC. | $56.45 | 2023-2024 | Qutenza |
| Catalyst Pharmaceuticals, INC. | $53.61 | 2020-2024 | |
| Assertio Therapeutics, INC. | $43.55 | 2019-2020 | |
| Janssen Biotech, INC. | $43.48 | 2025 | |
| Life Molecular Imaging Ltd | $41.56 | 2025 | Neuraceq |
| Axsome Therapeutics, INC. | $41.07 | 2022-2023 | Sunosi |
| Arbor Pharmaceuticals, INC. | $40.32 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $39.34 | 2024 | Wainua |
| Genentech, INC. | $38.47 | 2024-2025 | Ocrevus |
| Otsuka America Pharmaceutical, INC. | $37.86 | 2023 | Nuedexta |
| Adamas Pharmaceuticals, INC. | $37.57 | 2019-2020 | |
| Cycle Pharmaceuticals INC | $35.64 | 2025 | Bafiertam |
| Merz North America, INC. | $29.58 | 2020 | |
| Springworks Therapeutics, INC. | $25.99 | 2025 | Gomekli |
| Collegium Pharmaceutical, INC. | $25.79 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.24 | 2025 | Hyqvia |
| Bioventus LLC | $22.29 | 2023 | L300 Go System |
| Saol Therapeutics INC. | $20.89 | 2019 | |
| Coopersurgical, INC. | $18.17 | 2024 | Paragard T 380a |
| Azurity Pharmaceuticals, INC. | $18.13 | 2024 | Horizant |
| Advanced Respiratory, INC | $17.41 | 2019 | |
| Akcea Therapeutics, INC. | $16.33 | 2021 | |
| Travere Therapeutics, INC. | $15.53 | 2019 | |
| Merck Sharp & Dohme LLC | $15.26 | 2020 | |
| Alfasigma USA, INC. | $15.25 | 2020 | |
| Boston Scientific Corporation | $14.94 | 2022 | |
| Insightec,INC | $13.84 | 2025 | Exablate |
| Sanofi-Aventis U.S. LLC | $7.00 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,373.98 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.